David Arkowitz
CIK 1296999 · Chief Financial Officer · last filed 2025-11-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$6.60M
Companies
10
Total Filings
72
Lifetime Open-Market Net
$88.4K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IBIO | Director | 18,382 | $1.69 | $31.1K | $50.0K | 3 | 2025-11-24 |
| KINETA, INC./DE (KA) Delisted | Director | — | $0.57 | — | $0 | 2 | 2024-09-05 |
| MCRB | Chief Financial Officer | 182,442 | $5.70 | $1.04M | -$9.7K | 8 | 2024-02-16 |
| F-star Therapeutics, Inc. (FSTX) Delisted | Director | 0 | $7.12 | $0 | $0 | 3 | 2023-03-09 |
| KINETA, INC./DE (YMTX) Delisted | Director | 4,347 | $13.23 | $57.5K | $0 | 2 | 2021-06-04 |
| FLXN | Chief Financial Officer | 220,719 | $25.05 | $5.53M | $102.9K | 17 | 2021-05-12 |
| F-star Therapeutics, Inc. (SBPH) Delisted | Director | 37,929 | — | — | $30.6K | 12 | 2020-11-23 |
| KINETA, INC./DE (PTI) Delisted | Director | — | — | — | $0 | 2 | 2020-07-01 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | EVP, CFO and CBO | 1,806 | — | — | -$85.4K | 20 | 2011-06-01 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Chief Financial Officer | — | — | — | $0 | 1 | 2007-03-14 |
Recent Filings · Page 5 of 8
72 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-03-08 | KINETA, INC./DE (PTI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-03-05 | FLXN | Grant (A) | +36,000 | $0 | EDGAR |
| 2019-01-04 | FLXN | Other (J) | +922 | $9.7K | EDGAR |
| 2018-11-13 | FLXN | Buy (P) | +4,000 | $66.2K | EDGAR |
| 2018-08-10 | FLXN | Buy (P) | +4,000 | $93.7K | EDGAR |
| 2018-06-19 | F-star Therapeutics, Inc. (SBPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-04 | FLXN | Grant (A) | +30,000 | $0 | EDGAR |
| 2017-08-07 | F-star Therapeutics, Inc. (SBPH) Delisted | Buy (P) | +2,500 | $30.6K | EDGAR |
| 2017-06-16 | F-star Therapeutics, Inc. (SBPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-11-23 | F-star Therapeutics, Inc. (SBPH) Delisted | Grant (A) | +4,386 | $40.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.